Note
Absence of Influence of Concomitant Administration of Rabeprazole on the Pharmacokinetics of Tacrolimus in Adult Living-donor Liver Transplant Patients: A Case–control Study

https://doi.org/10.2133/dmpk.24.458Get rights and content

Summary:

This study assesses the effects of rabeprazole on the pharmacokinetics of tacrolimus, considering the cytochrome P450 (CYP) 2C19 and CYP3A5 genotypes of living-donor liver transplant patients (native intestine) and their corresponding donors (graft liver). We examined the concentration/dose ratio of tacrolimus in transplant patients treated with (n = 17) or without (n = 38) rabeprazole at 10 mg/day on postoperative days 22–28. A stratified analysis revealed no significant differences between the control and rabeprazole groups in the median (range) concentration/dose ratio of tacrolimus [(ng/mL)/(mg/day)] for CYP2C19 extensive/intermediate metabolizers [2.71 (1.00-6.15) versus 2.55 (0.96-9.25); P= 0.85] and for poor metabolizers [4.92 (2.44-7.00) versus 3.82 (2.00-7.31); P=0.68], respectively. Even based on the classification of CYP2C19 genotypes of donors, no significant difference in the concentration/dose ratio of tacrolimus was found for the two groups (CYP2C19 extensive/intermediate metabolizers, P=0.52; poor metabolizers, P=0.51). The same was observed for CYP3A5* 1 carriers (P = 0.97 for native intestine; P = 0.87 for graft liver) and CYP3A5*3/*3 carriers (P = 0.89 for native intestine; P = 0.56 for graft liver). These findings suggest a safer dosing and monitoring of tacrolimus coadministered with rabeprazole early on after liver transplantation regardless of the CYP2C19 and CYP3A5 genotypes of transplant patients and their donors.

References (24)

  • M. Miura et al.

    Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients

    Biopharm. Drug Dispos.

    (2007)
  • K. Hosohata et al.

    Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients

    Drug Metab. Dispos.

    (2009)
  • This work was supported in part by the 21 st Century Center of Excellence (COE) Program "Knowledge Information Infrastructure for Genome Science'' by a grant-in-Aid from the Japan Health Sciences Foundation for "Research on Health Sciences Focusing on Drug Innovation'', and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. K. H. was supported as a Research Assistant by the 21st Century COE program "Knowledge Information Infrastructure for Genome Science”

    View full text